<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00683046</url>
  </required_header>
  <id_info>
    <org_study_id>11300A</org_study_id>
    <nct_id>NCT00683046</nct_id>
  </id_info>
  <brief_title>T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies</brief_title>
  <official_title>T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Chicago</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objectives:

        1. To evaluate disease free survival after Campath 1H-based in vivo T-cell depletion and
           non-myelo-ablative ablative stem cell transplantation in patients with hematologic
           malignancies.

        2. To evaluate the incidence and severity of acute and chronic GVHD after Campath 1H-based
           in vivo T-cell depletion, in patients with hematologic malignancies undergoing
           non-myelo-ablative stem cell transplantation.

        3. To evaluate engraftment and chimerism after Campath 1H-based in vivo T-cell depletion
           and non-myelo-ablative ablative stem cell transplantation in patients with hematologic
           malignancies.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2001</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Median Disease-free Survival</measure>
    <time_frame>Patients evaluated continuously with disease specific re-evaluation at day 30, 3 months, 6 months, 1 year, and as indicated thereafter up to 10 years</time_frame>
    <description>All patients were administered the following drugs;
Fludarabine 30mg/m2 intravenously daily at the same time over 30 min on days -7,-6,-5,-4, and -3
Melphalan 140mg/m2 IV on day -2
Stem cell infusion on day 0
Campath 20mg IV on day -7,-6,-5,-4, and -3</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Median Overall Survival</measure>
    <time_frame>Patients evaluated continuously with disease specific re-evaluation at day 30, 3 months, 6 months, 1 year, and as indicated thereafter up to 10 years</time_frame>
    <description>All patients were administered the following drugs;
Fludarabine 30mg/m2 intravenously daily at the same time over 30 min on days -7,-6,-5,-4, and -3
Melphalan 140mg/m2 IV on day -2
Stem cell infusion on day 0
Campath 20mg IV on day -7,-6,-5,-4, and -3</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">204</enrollment>
  <condition>Acute Myelogenous Leukemia</condition>
  <condition>Lymphoid Leukemia</condition>
  <condition>Chronic Myelogenous Leukemia</condition>
  <condition>Malignant Lymphoma</condition>
  <condition>Hodgkin's Disease</condition>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <condition>Myeloproliferative Disorder</condition>
  <condition>Anemia, Aplastic</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <arm_group>
    <arm_group_label>Drug Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Fludarabine 30 mg/m2 intravenously daily at the same time over 30 minutes on days -7,-6,-5,4,-3,.</description>
    <arm_group_label>Drug Intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <description>Melphalan 140 mg/m2 IV on day -2.</description>
    <arm_group_label>Drug Intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Stem cells</intervention_name>
    <description>Stem cell infusion on day 0.</description>
    <arm_group_label>Drug Intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Campath</intervention_name>
    <description>Campath, 20 mg IV on day -7, 6, -5, -4, and -3.</description>
    <arm_group_label>Drug Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Zubrod performance status 2 (See Appendix B).

          -  Life expectancy is not severely limited by concomitant illness.

          -  Adequate cardiac and pulmonary function. Patients with decreased LVEF or PFTS will be
             evaluated by cardiology or pulmonary prior to enrollment on this protocol.

          -  Serum creatinine &lt;1.5 mg/dL or Creatinine Clearance &gt;50 ml/min .

          -  Serum bilirubin 2.0 mg/dl, SGPT &lt;3 x upper limit of normal

          -  No evidence of chronic active hepatitis or cirrhosis.

          -  HIV-negative

          -  Patient is not pregnant

          -  Patient or guardian able to sign informed consent.

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew Artz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Chicago</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 21, 2008</study_first_submitted>
  <study_first_submitted_qc>May 22, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 23, 2008</study_first_posted>
  <results_first_submitted>February 14, 2014</results_first_submitted>
  <results_first_submitted_qc>February 14, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 31, 2014</results_first_posted>
  <last_update_submitted>October 7, 2016</last_update_submitted>
  <last_update_submitted_qc>October 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Relapsed or refractory acute myelogenous or lymphoid leukemia.</keyword>
  <keyword>Acute myeloid or lymphocytic leukemia in first remission at high-risk for recurrence.Chronic myelogenous leukemia in accelerated phase or blast-crisis.</keyword>
  <keyword>Chronic myelogenous leukemia in chronic phase</keyword>
  <keyword>Chronic myelogenous leukemia in accelerated phase or blast-crisis</keyword>
  <keyword>Recurrent or refractory malignant lymphoma or Hodgkin's disease.</keyword>
  <keyword>Chronic lymphocytic leukemia, relapsed or with poor prognostic features.</keyword>
  <keyword>Myeloproliferative disorder (polycythemia vera, myelofibrosis) with poor prognostic features.</keyword>
  <keyword>Severe aplastic anemia after failure of immunosuppressive therapy.</keyword>
  <keyword>Myelodysplastic syndromes (including PNH)</keyword>
  <keyword>Multiple myeloma at high risk for disease recurrence.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Anemia, Aplastic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Alemtuzumab</mesh_term>
    <mesh_term>Melphalan</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>T-cell Depleted Allogeneic Stem Cell Transplantation</title>
          <description>All patients were administered the following drugs;
Fludarabine 30mg/m2 intravenously daily at the same time over 30 min on days -7,-6,-5,-4, and -3
Melphalan 140mg/m2 IV on day -2
Stem cell infusion on day 0
Campath 20mg IV on day -7,-6,-5,-4, and -3</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="204"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="204"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>T-cell Depleted Allogeneic Stem Cell Transplantation</title>
          <description>All patients were administered the following drugs;
Fludarabine 30mg/m2 intravenously daily at the same time over 30 min on days -7,-6,-5,-4, and -3
Melphalan 140mg/m2 IV on day -2
Stem cell infusion on day 0
Campath 20mg IV on day -7,-6,-5,-4, and -3</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="204"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.0" spread="12.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Median Disease-free Survival</title>
        <description>All patients were administered the following drugs;
Fludarabine 30mg/m2 intravenously daily at the same time over 30 min on days -7,-6,-5,-4, and -3
Melphalan 140mg/m2 IV on day -2
Stem cell infusion on day 0
Campath 20mg IV on day -7,-6,-5,-4, and -3</description>
        <time_frame>Patients evaluated continuously with disease specific re-evaluation at day 30, 3 months, 6 months, 1 year, and as indicated thereafter up to 10 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>T-cell Depleted Allogeneic Stem Cell Transplantation</title>
            <description>All patients were administered the following drugs;
Fludarabine 30mg/m2 intravenously daily at the same time over 30 min on days -7,-6,-5,-4, and -3
Melphalan 140mg/m2 IV on day -2
Stem cell infusion on day 0
Campath 20mg IV on day -7,-6,-5,-4, and -3</description>
          </group>
        </group_list>
        <measure>
          <title>Median Disease-free Survival</title>
          <description>All patients were administered the following drugs;
Fludarabine 30mg/m2 intravenously daily at the same time over 30 min on days -7,-6,-5,-4, and -3
Melphalan 140mg/m2 IV on day -2
Stem cell infusion on day 0
Campath 20mg IV on day -7,-6,-5,-4, and -3</description>
          <units>Days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="204"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="333" lower_limit="253" upper_limit="386"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Overall Survival</title>
        <description>All patients were administered the following drugs;
Fludarabine 30mg/m2 intravenously daily at the same time over 30 min on days -7,-6,-5,-4, and -3
Melphalan 140mg/m2 IV on day -2
Stem cell infusion on day 0
Campath 20mg IV on day -7,-6,-5,-4, and -3</description>
        <time_frame>Patients evaluated continuously with disease specific re-evaluation at day 30, 3 months, 6 months, 1 year, and as indicated thereafter up to 10 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>T-cell Depleted Allogeneic Stem Cell Transplantation</title>
            <description>All patients were administered the following drugs;
Fludarabine 30mg/m2 intravenously daily at the same time over 30 min on days -7,-6,-5,-4, and -3
Melphalan 140mg/m2 IV on day -2
Stem cell infusion on day 0
Campath 20mg IV on day -7,-6,-5,-4, and -3</description>
          </group>
        </group_list>
        <measure>
          <title>Median Overall Survival</title>
          <description>All patients were administered the following drugs;
Fludarabine 30mg/m2 intravenously daily at the same time over 30 min on days -7,-6,-5,-4, and -3
Melphalan 140mg/m2 IV on day -2
Stem cell infusion on day 0
Campath 20mg IV on day -7,-6,-5,-4, and -3</description>
          <units>Days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="204"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="547" lower_limit="378" upper_limit="946"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>180 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>T-cell Depleted Allogeneic Stem Cell Transplantation</title>
          <description>All patients were administered the following drugs;
Fludarabine 30mg/m2 intravenously daily at the same time over 30 min on days -7,-6,-5,-4, and -3
Melphalan 140mg/m2 IV on day -2
Stem cell infusion on day 0
Campath 20mg IV on day -7,-6,-5,-4, and -3</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="69" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Blood and lymphatic system disorders, other</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Bone marrow hypocellular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Thrombotic thrombocytopenic purpura</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Endocarditis infective</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Heart Failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdomial infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Bladder infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Bone infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Catheter related infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Infection and infestations - other, specify</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Post operative hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Treatment related secondary malignancy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cognitive disturbance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Chronic kidney disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Vaginal hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Adult Respiratory distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Bronchopulmonary hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thromboembolic event</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Andrew Artz</name_or_title>
      <organization>University of Chicago Medicine</organization>
      <phone>773-834-8980</phone>
      <email>aartz@medicine.bsd.uchicago.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

